Electronic Data Capture
Venue: Loews L\'Enfant Plaza
|Event Date/Time: Nov 12, 2003||End Date/Time: Nov 14, 2003|
There are now as many technological options for the EDC movement as there are opinions on how to best incorporate These technologies into the EDC process. The 8th Annual Electronic Data Capture conference is designed to promote an exchange of ideas and attempt to reduce the frustrations being experienced by many EDC developers and to lead to a more successful future development of EDC.
On Day One, Wednesday, November 12th, we present two pre-conference workshops. The first pre-conference workshop, How EDC can Maximize the Efficiency of your Clinical Trial Conduct facilitated by Forest Laboratories, provides you with general information on how to establish the business case for EDC, the impact of implementation and measuring performance. The second pre-conference workshop discusses the utility of Electronic Patient Diaries and the comparison to paper.
One Day Two, first day of the main conference, Thursday, November 13th, features presentations from AstraZeneca, Pfizer, First Consulting Group, eResearch Technology and Genzyme Corporation. The EDC experts from these companies speak from their experiences and present on the following topics:
The source of the industry's hesitation to adopt EDC
A detailed recount of Pfizer's transition from paper to electronic
Increasing clinical research capacity through EDC implementation
Minimizing the impact of change through systems integration and vendor selection
EDC on a smaller scale, the biotech perspective
These presentations are followed by a panel discussion on the advantages and disadvantages of different EDC Implementation Strategies..
The final day of the conference, Friday, November 14th, features a presentation from Wyeth on maximizing user benefit through seamless integration of clinical data and systems. This presentation is followed by a session discussing if there is future for clinical trial IT vendors, facilitated by Forrester Research, followed by a panel discussion on the dysfunctional relationship between pharmaceutical companies and vendors.